Results 101 to 110 of about 24,145,261 (292)

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma [PDF]

, 2017
The 2016 revised World Health Organization (WHO) classification includes several provisional borderline categories for lymphoma cases that do not clearly fit into one entity, such as B-cell lymphoma, unclassifiable (BCLU), with features intermediate ...
Pantanowitz, Liron, Sulfaro, Sandro, Gloghini, Annunziata, Carbone, Antonino   +3 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Spontaneous resolution of untreated diffuse large B‐cell lymphoma of maxillary bone after incisional biopsy

Clinical Case Reports, 2019
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous group of lymphomas which require multiagent therapy for remission induction and are associated with relapse in more than 40% of patients.
Lainey Flatow‐Trujillo, Khine Win, Amy Jencks, Leslie Andritsos, Cecilia Arana Yi   +4 more
doaj   +1 more source

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

Haematologica, 2010
Background BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome.
Jesse Shustik, Guangming Han, Pedro Farinha, Nathalie A. Johnson, Susana Ben Neriah, Joseph M. Connors, Laurie H. Sehn, Douglas E. Horsman, Randy D. Gascoyne, Christian Steidl   +9 more
doaj   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Primary diffuse cutaneous large B-cell lymphoma, anaplastic type

, 2012
In the article the case of primary diffuse cutaneous large B-cell lymphoma, anaplastic type is ...
S. V. Antonyuk, V. A. Yablunovsky, V. I. Probachay   +2 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Genetic background of relapsing lymphoid neoplasms : comprehensive genetic characterization of primary - relapse pairs by chromosomal copy number and mutational analysis [PDF]

, 2016
Diffuse large B-cell lymphoma (DLBCL) is the most frequent tumor of the lymphoid system. Standard first line therapy is successful in the majority of cases, however about 30% of DLBCL are either refractory to it or relapse after a period of ...
Juškevičius, Darius
core   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

Childhood testicular diffuse large B-cell lymphoma

Клиническая онкогематология, 2013
Non-Hodgkin’s lymphomas with primary testis involvement is a rare heterogeneous group of lymphoid tumours. In adults testicular lymphomas (TL) are characterized by aggressive clinical progression, frequent relapses and metastases to CNS, and poor ...
T. T. Valiev, A. M. Kovrigina, I. N. Serebryakova, E. V. Mikhailova, A. V. Popa, G. L. Mentkevich   +5 more
doaj   +1 more source